Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of a Fractional Adult Dose of the Malaria Vaccine R21/Matrix-M
NCT07194668Phase 4Not yet recruiting
- Sponsor
- University of Oxford
- Start
- Aug 2026
- Primary completion
- Dec 2026
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 4 trial of R21/Matrix-M in malaria, sponsored by University of Oxford. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
R21/Matrix-M
03
Conditions
malaria
Beyond the preview
Go deeper on NCT07194668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07194668.